NKGN

NKGen Biotech Inc. · NASDAQ

Sector Finance
Industry Financial Conglomerates
Website nkgenbiotech.com
Employees(FY) -
ISIN US65488A1016

Performance

+29.35%

+120.77%

+49.71%

-46.22%

-76.73%

YTD

-78.16%

Profile

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Advanced Technical Analysis

Technical Analysis of NKGN 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 83, indicating robust upward momentum, while the Technical Score of 70 further supports this positive outlook. However, the Oscillators Score of 56 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NKGN

Stock Rank

Recent News & Updates

2024-12-02 03:05
NKGen Biotech Selected as Stalking Horse Bidder for NKMax(Globenewswire)
2024-11-26 03:15
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel(Globenewswire)
2024-10-28 20:05
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference(Globenewswire)
2024-10-14 20:05
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)(Globenewswire)
2024-10-07 20:05
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference(Globenewswire)
2024-09-11 20:05
NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial(Globenewswire)
2024-09-02 20:05
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-22 04:40
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report(Globenewswire)
2024-07-29 20:05
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer's Association International Conference(Globenewswire)
2024-07-17 20:05
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International Conference(Globenewswire)
2024-07-14 20:05
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors(Globenewswire)
2024-06-12 01:05
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024(Globenewswire)
2024-06-02 20:05
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024(Globenewswire)
2024-05-23 05:05
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting(Globenewswire)
2024-05-20 21:53
NKGN Stock Earnings: NKGen Biotech Reported Results for Q1 2024(Investorplace)
2024-05-19 23:41
NKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring Today(Investorplace)
2024-05-19 20:05
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease(Globenewswire)
2024-05-15 20:05
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition(Globenewswire)
2024-04-28 20:00
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinsons Disease(Yahoo Finance)
2024-04-25 04:05
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit(Globenewswire)
2024-04-24 04:45
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting(Globenewswire)
2024-04-18 04:05
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit(Globenewswire)
2024-04-16 11:53
NKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023(Investorplace)
2024-04-10 20:05
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs(Globenewswire)
2024-03-25 04:05
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference(Globenewswire)
2024-03-05 18:52
Why Is NKGen Biotech (NKGN) Stock Up 62% Today?(Investorplace)
2024-03-03 19:00
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference(Globenewswire)
2024-02-06 19:57
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies(Yahoo Finance)
2023-12-28 18:30
NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial(Yahoo Finance)
2023-12-28 03:05
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease(Globenewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.